Get the StoQuant digest — free
Free StoQuant digest by email. No account needed.
See today's research picks.
AZN vs VRTX — Stock Comparison
Compare AZN and VRTX side-by-side on StoQuant: AZN Q-Score 45 vs VRTX 68; analyst signal 61 vs 75. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.
Side-by-side snapshot
- AZN — AstraZeneca PLC · Health Care · market cap $263.77B · Q-Score verdict Hold (45.0, grade C) · analyst signal 61/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: technicals 37/100, analyst consensus 28/100 · weakest signals: ML forecast 5/100. Full AZN research.
- VRTX — VERTEX PHARMACEUTICALS INC · Health Care · market cap $132.06B · Q-Score verdict Strong Buy (68.0, grade A) · analyst signal 75/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: technicals 84/100, competitive moat 83/100 · weakest signals: analyst consensus 76/100, earnings quality 20/100. Full VRTX research.
What you can compare
- Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
- Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
- Insider activity: Cluster scores and recent Form 4 buying.
- Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
- Strategic edges: Competitive moat and durable advantage analysis.
- Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
- Macro context: Market regime and sector rotation alignment.
Deep dive: AZN research · VRTX research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →
Register founding interest — Pro $29/mo or Power $79/mo
Paid plans aren’t for sale yet. Leave your email to lock founding pricing (Pro $29, Power $79); we’ll reach out personally.